Limited synergistic effect of antisense oligonucleotides against bcr-abl and transferrin receptor mRNA in leukemic cells in culture

• Type: Article in International Scientific Journal
• Date: 2000

Authors

Vasconcelos, MH (Author) Other; Beleza, SS (Author) Other; Quirk, C (Author) Other; Maia, LF (Author) Other; Sambade, C (Author) Other; Guimaraes, JE (Author) FMUP

Journal

Title: Cancer Letters

Vol. 152

Pages: 135-143

ISSN: 0304-3835

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 24 Citations

Scopus - 26 Citations

Scientific classification

FOS: Medical and Health sciences > Clinical medicine

Other information

Authenticus ID: P-001-048

DOI: 10.1016/s0304-3835(99)00441-3

Abstract (EN): The synergistic use of antisense oligonucleotides (ASOs) towards the bur-abl and the transferrin receptor (TfR) mRNA was studied in a chronic myeloid leukemia (CML) cell line, aiming to improve the efficiency of individual ASO treatment. At 20 muM concentration, bcr-abl ASOs reduced cell growth by 40% and was specific for cells that have the translocation: there was a 34% reduction of BCR-ABL protein. The TfR ASO reduced cell growth by 20% and decreased TfR protein by 24%. The ASOs were more potent at reducing cell growth when used in combination (respectively, -20 and -17% than bcr-abl ASO and TW ASO when used individually at the 10 muM concentration), thus we postulate that there is synergism of action. Cell cycle analysis also revealed that the sub-G1 peak was bigger in the synergistic treatment.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9